• Mr.liuhaitao
    Tel: 18733185280

  • Mobile:
  • Tel:18733185280
  • Fax:+86-311-85370020
  • Province/state:Hebei Province
  • City:Shijiazhuang
  • Street:Building 8, 388 Jialilue Road
  • MaxCard:
    About us
  • Welcome To Our Site!

  • Founded by a group of veterans from the US biopharmaceutical industry in 2004, Sundia MediTech Company Ltd. is now a leading Shanghai-based CRO company providing drug discovery and development services worldwide. In 2007, Sundia successfully merged with United PharmaTech and formed an alliance with HD Biosciences. With our technical expertise and excellent research facilities, we offer broad and integrated chemical synthesis (custom synthesis, library design and synthesis), medicinal chemistry (hit generation, lead optimization, and preclinical development), biological (early hit screening, assay development, in vitro and in vivo pharmacology, in vitro and in vivo DMPK), new technology platforms (molecular diagnostics and PBSDD and nanotechnology), and pharmaceutical development (process research and development, API manufacture, pre-formulation and formulation, analytical and QA/QC, CMC and regulatory submission) services.

    Since its founding in 2004, the company's CRO service business has been growing at an amazing rate. It was consecutively named as one of the top 50 most valuable companies for investment in China in 2007 and 2008. In 2008, with its 928% revenue growth, Sundia ranked #52 in the Deloitte Technology Fast 500 Asia Pacific list and #16 in the Fast 50 China list. Our expansion through partnerships has been driven by growing demand from our clients. In the past 5 years, Sundia has successfully established collaborations with over 100 client companies in North America, Europe, and Japan.

    For Sundia, our professional leadership is an important asset. Our management team is made up of scientists with advanced degrees or training and who have extensive working/management experience in North America. Our team has rich experience in organic synthesis, medicinal chemistry, process chemistry, biology, business management, and law. Our research team comprises over 600 employees (HQ), among which 70% have a Ph.D. or a MS; About 8% are overseas returnees.
  • Process Capability :   Sundia has been providing process development and scale up production service since 2004. Our services include the laboratory works such as process research and small scale synthesis of APIs which are used for preclinical and pre-formulation studies. Our services further extend to relatively large scale kilo lab synthesis as our client's program moves to phase I clinical studies. At this stage, we can help client identify the synthesis route and optimize the process, followed by non-GMP and/or GMP-required synthesis of intermediates and APIs. As your clinical program moves forward, we can make more intermediates and APIs to support your Phase II and III clinical trials and commercialization needs in our production site. We also provide service for our clients to develop better and/or n
    After-sale Service :   Analytical Development (ARD) is to support Chemical Process Development and Formulation Development during the pharmaceutical development. ARD offers GMP compliant Analytical testing services to the pharmaceutical and biotech companies. We are equipped with state-of-the-art analytical instruments. We deliver fast and reliable results and help our clients to achieve their goals of registration. Sundia ARD team offers a wealth of experience and expertise in every aspect of analytical support ranging from method development to regulatory submissions. Our team also has experience with SFDA filing to get Clinical Trial Approval in China. Key Services: ? Method development and validation for starting material, intermediates, API, and dosage forms ? Assay/potency ? Impurity/degradat

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog